Difference between revisions of "Axitinib (Inlyta)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(updated content)
m (categories)
Line 19: Line 19:
 
==References==
 
==References==
 
<references/>
 
<references/>
 +
 +
[[Category:Drug index]]
 +
[[Category:Chemotherapy]]
 +
[[Category:Tyrosine kinase inhibitors]]
 +
[[Category:VEGF inhibitors]]
 +
[[Category:PDGFR inhibitors]]
 +
[[Category:Renal cancer medications]]
 +
[[Category:Thyroid cancer medications]]
 +
[[Category:Drugs FDA approved in 2012]]

Revision as of 01:13, 8 October 2012

FDA approved 1/27/2012 Also known as AG013736.

General information

Class/mechanism: Tyrosine kinase inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, and VEGFR-3, which interferes with tumor angiogenesis, growth, and cancer progression.[1][2][3]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

References